Search clinical trials for: JNJ-26113100

Total 870 results

Janssen Research & Development, LLC

Completed

A Study to Evaluate the Adherence of 2 Strengths of Newly Manufactured Samples and Aged Samples of a New Formulation (JNJ-35685-AAA-G016 and JNJ-35685-AAA-G021) of Fentanyl Transdermal System Compared With Duragesic Fentanyl Transdermal Patch in Healthy Participants

Healthy

United States
Janssen Pharmaceutical K.K.

Completed

Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia

Alzheimer's Disease

Japan
K.N. Roy Chengappa
University of Pittsburgh; National Institutes of Health (NIH); Virginia Commonwealth...

Completed

Novel Smoking Cessation Drug for Schizophrenia (TRENDS)

Smoking Cessation

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate Safety and Tolerability of JNJ-61178104 in Healthy Participants

Healthy

Belgium
Janssen Pharmaceutical K.K.

Terminated

A Study of JNJ-39758979 in Adult Japanese Patients With Moderate Atopic Dermatitis

Dermatitis, Atopic

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-42847922 in Healthy Japanese Male Participants

Healthy

Japan
Janssen-Cilag International NV

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54175446 in Healthy Male Participants

Healthy

Netherlands
Janssen Infectious Diseases BVBA

Completed

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-63623872 in Healthy Japanese Adult Participants

Healthy

United Kingdom
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ 10229570-AAA to Evaluate Safety and Tolerability in Japanese Participants With Acne Vulgaris

Acne Vulgaris

Japan
National Institute of Allergy and Infectious Diseases...
National Institutes of Health (NIH); Janssen, LP

Recruiting

An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge

Dengue

United States
Bausch Health Americas, Inc.

Completed

A Study of a New Drug Treatment for Acne

Acne Vulgaris

United States
Janssen-Cilag International NV

Completed

A Study to Investigate Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of JNJ-54175446 in Healthy Participants

Healthy

Belgium
Crucell Holland BV

Completed

A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult Volunteers

Respiratory Tract Infections | Respiratory Syncytial Viruses

United States
Aragon Pharmaceuticals, Inc.

Completed

Bioavailability Study of 3 Tablet Formulations vs. Capsule Formulation of JNJ-56021927 in Fasting Healthy Male Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study in Healthy Adults to Evaluate the Safety and Immunogenicity of Different Doses of JNJ-63871860

Healthy

United States
Janssen Pharmaceutical K.K.

Recruiting

A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Generalized Pustular Psoriasis | Erythrodermic Psoriasis

Japan
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors

Advanced Stage Solid Tumors

Spain
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors

Neoplasms

Canada, Israel, Spain
Janssen Research & Development, LLC

Completed

A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer

Prostatic Neoplasms

United States, United Kingdom
Janssen Research & Development, LLC

Completed

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1)

Multiple Myeloma

United States, Japan
Janssen Research & Development, LLC

Completed

A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors

Neoplasms

United States, Canada
Janssen Research & Development, LLC

Completed

A Study to Compare Two Different Subcutaneously-administered JNJ-64304500 Formulations in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple Dose

Obesity

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Research Study of JNJ-26854165 to Determine the Safety and Dose in Patients With Advanced Stage or Refractory Solid Tumors.

Neoplasms
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-38431055 in Healthy Male Volunteers

Diabetes Mellitus, Type 2
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Single and Multiple Dose Study to Explore the Safety and Pharmacokinetics of JNJ-39758979 In Healthy Male Volunteers of Either Caucasian or Japanese Descent

Healthy

United States
Janssen Research & Development, LLC

Withdrawn

Study to Investigate the Food Effect and Oral Bioavailability of Tablet Formulations Relative to Suspension Formulation of JNJ-54416076 in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Terminated

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64140284 in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery (TEXT-TKR)

VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery

Belgium, Italy, Malaysia, Latvia, Spain, Turkey, Bulgaria, United States, Lithuania, Russian Federation, Ukraine, Japan, Argentina, Brazil, Canada, Poland
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42721458 in Healthy Male Participants

Healthy

Belgium
Aragon Pharmaceuticals, Inc.

Completed

Study to Assess Drug-Drug Interaction Between Itraconazole or Gemfibrozil and JNJ-56021927

Healthy

United States
Janssen-Cilag International NV

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-55308942 in Healthy Male and Female Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study of JNJ-42847922 (Seltorexant) in Healthy Participants

Healthy

Netherlands
Janssen Sciences Ireland UC

No longer available

Pre-Approval Access to JNJ-53718678 for the Treatment of Respiratory Syncytial Virus (RSV) Infection in (a) Immunocompromised Adult and Pediatric Participants

Respiratory Syncytial Virus
Janssen Research & Development, LLC

Completed

A Study of Seltorexant in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Terminated

Safety & Immunogenicity of JNJ-64041757, Live-attenuated Double-deleted Listeria Immunotherapy, in Subjects With Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Aragon Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function

Hepatic Impairment

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants

Healthy

Belgium
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

An Efficacy and Safety Study of JNJ-38518168 in Adult Participants With Rheumatoid Arthritis

Rheumatoid Arthritis

Poland, United Kingdom, Taiwan, Spain, Korea, Republic of, Belgium, Russian Federation, Czech Republic, Netherlands, Ireland
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy

Diabetic Neuropathy

United States
Janssen Research & Development, LLC

Completed

A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder

Depressive Disorder, Major

Belgium, United Kingdom, Germany, United States, Netherlands
Janssen Research & Development, LLC

Not yet recruiting

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-10)

Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis (ANTHEM-UC)

Colitis, Ulcerative

Korea, Republic of, Canada, United States, Australia, Czechia, Malaysia, Germany, Turkey, Japan, Belgium, Hungary, Italy, Spain, China, Poland, United Kingdom, Brazil, France, Argentina, Romania, India
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-64281802 for the Prevention of Dengue Infection

Dengue

Mexico, Malaysia, Brazil, Colombia, Puerto Rico, Panama, Peru, Philippines, Thailand
Janssen Research & Development, LLC

Recruiting

A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function

Hepatic Impairment

United States
University of Oxford
Janssen Pharmaceutica

Terminated

MIcroglial Colony Stimulating Factor-1 Receptor (CSF1R) in Alzheimer's Disease (MICAD)

Alzheimer Disease | Mild Cognitive Impairment

United Kingdom
Janssen Research & Development, LLC

No longer available

Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

Belgium, Iceland, Portugal, Slovenia
Janssen Research & Development, LLC

Completed

Study to Evaluate Efficacy, Safety and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder Without Psychiatric Comorbidity

Insomnia

Germany, United States, Netherlands
Janssen Research & Development, LLC

Approved for marketing

Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

Brazil, Germany, Italy, Netherlands, Romania, Switzerland, United Kingdom
Janssen Research & Development, LLC

Completed

A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795

Fatty Liver Disease

United States

3

Subscribe